oxidopamine has been researched along with Combined Immunodeficiency, X-Linked in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Samata, B | 1 |
| Kikuchi, T | 1 |
| Miyawaki, Y | 1 |
| Morizane, A | 1 |
| Mashimo, T | 1 |
| Nakagawa, M | 1 |
| Okita, K | 1 |
| Takahashi, J | 1 |
1 other study available for oxidopamine and Combined Immunodeficiency, X-Linked
| Article | Year |
|---|---|
X-linked severe combined immunodeficiency (X-SCID) rats for xeno-transplantation and behavioral evaluation.
Topics: Animals; Cell Culture Techniques; Cell Survival; Dopaminergic Neurons; Embryonic Stem Cells; Humans; | 2015 |